Influenza virus: A master of metamorphosis

Journal of Infection

Volumn 40, Issue 3, 2000, Pages 218-228

  De Jong, J C ^a   Rimmelzwaan, G F ^a   Fouchier, R A M ^a   Osterhaus, A D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENIC VARIATION; EPIDEMIC; INFLUENZA; INFLUENZA VIRUS; METAMORPHOSIS; REVIEW; VIRUS MORPHOLOGY; VIRUS VIRULENCE;

EID: 0033939183     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0652     Document Type: Review

References (76)

1. Jong JC de, Claas ECJ, Osterhaus ADME, Webster RG, Lim WL. A pandemic warning? Nature. 389:1997;554.
2. Claas ECJ, Osterhaus ADME, Beek R van. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 351:1998;472-477.
3. Webster RG, Hay AJ. The H5N1 influenza outbreak in Hong Kong: a test of pandemic preparedness. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;561-565 Blackwell Science, Oxford.
4. Lamb RA, Krug RM. Orthomyxoviruses: the viruses and their replication. Fields BN, Knipe DM, Howly PM. Fields Virology. 1996;1353-1395 Lippincott-Raven, Philadelphia.
5. Ruigrok RWH. Structure of influenza A, B, and C viruses. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;29-42 Blackwell Science, Oxford.
6. Webster RG, Bean WJ, Gorman TO, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Mircobiol Rev. 56:1992;152-179.
7. De Jong JC, de Ronde-Verloop FM, Veenendaal-van Herk TM, Weijers TF, Bijlsma K, Osterhaus ADME. Antigenic heterogeneity within influenza A(H3N2) virus strains. Bull WHO. 66:1988;47-55.
8. Katz JM, Webster RG. Antigenic and structural characterization of multiple subpopulations of H3N2 influenza virus from an individual. Virology. 165:1988;446-456.
9. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. Predicting the evolution of human influenza A. Science. 286:1999;1921-1925.
10. De Jong JC, Rimmelzwaan GF, Osterhaus ADME. Influenza pandemieën: verleden en toekomst. Ned Tijdschr Geneeskd. 143:1999;1988-1991.
11. Hemmes JH, Winkler KC, Kool SM. Virus survival as a seasonal factor in influenza and poliomyelitis. Nature. 188:1960;430-431.
12. Lavanchy D. The importance of global surveillance of influenza. Vaccine. 17:1999;S24-S25.
13. Potter CW. Chronicle of influenza pandemics. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;3-18 Blackwell Science, Oxford.
14. Masurel N. Serological characteristics of a "new" serotype of influenza A virus: the Hong Kong strain. Bull WHO. 41:1969;461-468.
15. McCullers JA, Wang GC, He S, Webster RG. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J Virol. 73:1999;7343-7348.
16. Kawaoka YS, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A virus in the 1957 and 1968 pandemics. J Virol. 63:1989;4603-4608.
17. Pensaert M, Ottis K, Vandeputte J, Kaplan MM, Bachman PA. Evidence for the natural transmission of influenza A virus from wild ducks to swine and its potential importance for man. Bull WHO. 59:1981;75-78.
18. Scholtissek C, Burger H, Bachman PA, Hannoun C. Genetic relatedness of hemagglutinins of the H1 subtype of influenza A viruses isolated from swine and birds. Virology. 129:1983;521-523.
19. Guan Y, Shortridge KF, Krauss S, Li PH, Kawaoka Y, Webster RG. Emergence of avian H1N1 influenza viruses in pigs in China. J Virol. 70:1996;8041-8046.
20. Tumová B, Vezníková D, Mensík J, Stumpa A. Surveillance of influenza in pig herds in Czechoslovakia in 1974-1979. I. Introduction of influenza epidemic A(H3N2) viruses into pig herds. Zentralbl Vet Med. B27:1980;517-523.
21. Mancini G, Donatelli I, Rozera C, Arangio Ruiz G, Buttó S. Antigenic and biochemical analysis of influenza 'A' H3N2 viruses isolated from pigs. Arch Virol. 83:1985;157-167.
22. Morin M, Girard C, ElAzhary Y, Fajardo R, Drolet R, Lagacé A. Severe proliferative and necrotizing pneumonia in pigs: a newly recognized disease. Can Vet J. 31:1990;837-839.
23. Shu LL, Lin IP, Wright SM, Shortridge KF, Webster RG. Evidence for interspecies transmission and reassortment of influenza A viruses in pigs in southern China. Virology. 202:1994;825-833.
24. De Jong JC, de Ronde-Verloop FM, Bangma PJ. Isolation of swine-influenza-like A(H1N1) viruses from man in Europe, 1986. Lancet. ii:1986;1329-1330.
25. Claas EC, Kawaoka Y, de Jong JC, Masurel N, Webster RG. Infection of children with avian-human reassortant influenza virus from pigs in Europe. Virology. 204:1994;453-457.
26. Scholtissek C, Naylor E. Fish farming and influenza pandemics. Nature. 331:1988;215.
27. Scholtissek C, Hinshaw VS, Olsen CW. Influenza in pigs and their role as the intermediate host. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;137-145 Blackwell Science, Oxford.
28. Yuen KY, Chan PKS, Peiris M. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 351:1998;467-471.
29. Dauer CC, Serfling RE. Mortality from influenza. 1957-58 and 1959-60. Am Rev Resp Dis. 83:1961;15-28.
30. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis. 178:1998;53-60.
31. Logan WPD. Mortality statistics. Proc Roy Soc Med. 44:1951;792-793.
32. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: Introducing a severity index. Am J Public Health. 87:1997;1944-1950.
33. Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 'Spanish' influenza virus hemagglutinin gene. Proc Natl Acad Sci USA. 96:1999;1651-1656.
34. Kawaoka Y, Webster RG. Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proc Natl Acad Sci USA. 85:1988;324-328.
35. Webster RG. 1918 Spanish influenza: The secrets remain elusive. Proc Natl Acad Sci USA. 96:1999;1164-1166.
36. Goto H, Kawaoka Y. A novel mechanism for the acquisition ofvirulence by a human influenza A virus. Proc Natl Acad Sci USA. 95:1998;10224-10228.
37. Taubenberger, JK, Genetic analysis of the virus which caused the influenza pandemic in 1918, Oral contribution at the 13th European Meeting on Influenza and its Prevention, 22-24 September 1999, Nice, France.
38. Dowdle WR. The 1976 experience. J Infect Dis. 176:1997;S69-S72.
39. Kendal AP, Goldfield M, Noble GR, Dowdle WR. Identification and preliminary antigenic analysis of swine influenza-like viruses isolated during an influenza outbreak at Fort Dix, New Jersey. J Infect Dis. 136:1977;S381-S385.
40. Saw TA, Lim W, Shortridge KF. Isolation of avian influenza A(H5N1) viruses from humans - Hong Kong, May-December 1997. Morb Mort Wkly Rep. 46:1997;1204-1207.
41. Suarez DL, Perdue ML, Cox N. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol. 1998;6678-6688.
42. Saito T, Horimoto T, Kawaoka Y, Senne DA, Webster RG. Emergence of a potentially pathogenic H5N2 influenza virus in chickens. Virology. 201:1994;277-284.
43. Subbarao K, Klimov A, Katz J. Characterization of an avian influenza A(H5N1) virus isolated from a child with a fatal respiratory illness. Science. 279:1998;393-396.
44. Xu XY, Subbarao K, Cox NJ, Guo YJ. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: Similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology. 261:1999;15-19.
45. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses: Were they the donors of the 'internal' genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci USA. 96:1999;9363-9367.
46. Ito T, Kawaoka Y. Avian influenza. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;126-136 Blackwell Science, Oxford.
47. Gorman OT, Bean WJ, Kawaoka Y, Donatelli I, Guo Y, Webster RG. Evolution of influenza A virus nucleoprotein genes: implications for origin of H1N1 human and classical swine viruses. J Virol. 65:1991;3704-3714.
48. Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol. 66:1992;1129-1138.
49. Shu L, Bean WJ, Webster RG. Evolution of the influenza A virus nucleoprotein from 1933 to 1988. J Virol. 67:1993;2723-2729.
50. Shortridge KF, Zhou NN, Guan Y. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology. 252:1998;331-342.
51. Masurel N. Swine influenza virus and the recycling of influenza-A viruses in man. Lancet. ii:1976;244-247.
52. Neumann G, Watanabe T, Ito H, Watanabe S. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA. 96:1999;9345-9350.
53. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. Ann Intern Med. 123:1995;518-527.
54. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;358-372 Blackwell Science, Oxford.
55. Leese J, Tamblyn SE. Pandemic planning. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;551-559 Blackwell Science, Oxford.
56. Voeten JTM, Brands R, Palache AM. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine. 17:1999;1942-1950.
57. Jennings R, Simms JR, Heath AW. Adjuvants and delivery systems for viral vaccines - mechanisms and potential. Brown F, Haaheim LR. Modulation of the Immune Response to Vaccine Antigens. Dev Biol Stand. 92:1998;19-28 Karger, Basel.
58. Rimmelzwaan GF, Baars M, Van Beek R. Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine. 17:1999;2512-2516.
59. Cryz SJ, Glöck R. Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system. Brown F, Haaheim LR. Modulation of the Immune Response to Vaccine Antigens. Dev Biol Stand. 92:1998;219-223 Karger, Basel.
60. Keitel WA, Piedra PA. Live cold-adapted, reassortant influenza vaccines (USA). Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;373-390 Blackwell Science, Oxford.
61. Berglund P, Fleeton MN, Smerdou C, Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine. 17:1999;497-507.
62. Webster RG. Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Clin Infect Dis. 28:1999;225-229.
63. Jong JC, Beyer WEP, Palache AM, Rimmelzwaan GF, Osterhaus ADME. The 1997/1998 influenza vaccine did not induce an adequate antibody response to the epidemic A(H3N2) virus strain in the elderly. J Med Virol. 61:2000;94-99.
64. Mullooly J, Bennett M, Hornbrook M, Williams W, Patriarca P, Rhodes P. Cost-effectiveness of influenza vaccination programs in an HMO: the experience of Kaiser Permanente, Northwest Region. Hannoun C, Klenk HD, Kendal AP, Ruben FL. Options for the Control of Influenza II. 1993;53-62 Elsevier Science Publishers, Amsterdam.
65. Aoki FY. Amantadine and rimantadine. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;457-476 Blackwell Science, Oxford.
66. Penn CR. Inhibitors of influenza neuraminidase. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. 1998;477-487 Blackwell Science, Oxford.
67. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: Neuraminidase inhibitors. Drugs. 56:1998;537-553.
68. Patriarca PA. New options for prevention and control of influenza. JAMA. 282:1999;75-77.
69. Hayden FG, Treanor JJ, Fritz RS. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA. 282:1999;1240-1246.
70. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults. JAMA. 282:1999;31-35.
71. Hayden FG, Osterhaus ADME, Treanor JJ. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N Engl J Med. 337:1997;874-880.
72. Mäkelä MJ, Pauksens K, Rostila T. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor, zanamivir, in the treatment of influenza: European study. J Infect. 40:2000;42-48.
73. Monto AS, Fleming DM, Henry D. Efficacy and safety of the neuraminidase inhibitor, zanamivir in the treatment of influenzaA and B virus infections. J Infect Dis. 180:1999;254-261.
74. Osterhaus ADME, de Jong JC. The control of influenza: antivirals as an adjunct to vaccines. Vaccine. 18:2000;779-780.
75. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 18:1996;64-76.
76. Woods JM, Bethell RC, Coates JAV. 4-Guanido-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 37:1993;1473-1479.